The FDA issued a warning letter to over-the-counter (OTC) drug manufacturer DSP Skin Care for quality lapses at its facility in Los Angeles, Calif., noting that the company had failed to remediate issues documented during agency inspections in 2018 and 2021.
Source: Drug Industry Daily